Natural product derived immune-regulatory agents

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We can now declare that the clinical goal of immune intervention as a therapeutic strategy for neoplastic, infectious, autoimmune and inflammatory diseases, has been achieved and in many instances obtained regulatory approval. Although, interest in and optimism for this approach has fluctuated, in the last 20 years, immunotherapy has progressed from trials with crude microbial mixtures and extracts to the sophisticated use of pure cultured bacterial, synthetized active moieties identified from crude extracts, analogues therefrom and agonists and antagonists identified during screening resulting in reproducible pharmacologically active compounds with multiple mechanisms of action. Our current understanding of the mechanism of action for immunoregulatory agents contributes to the future discovery of improved strategies to use these and future immunotherapies. In this review we have identified and discussed, those drugs that have been approved and or are in clinical development as immunoregulatory agents, emphasizing those derived from or associated with natural product.

Original languageEnglish (US)
Pages (from-to)5-15
Number of pages11
JournalInternational Immunopharmacology
Volume37
DOIs
StatePublished - Aug 1 2016

Fingerprint

Biological Products
Immunotherapy
Complex Mixtures
Autoimmune Diseases
Pharmaceutical Preparations
Therapeutics
Optimism

Keywords

  • Autoimmune
  • Infectious
  • Inflammatory diseases
  • Neoplastic

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Natural product derived immune-regulatory agents. / Talmadge, James E.

In: International Immunopharmacology, Vol. 37, 01.08.2016, p. 5-15.

Research output: Contribution to journalArticle

@article{a10fc2025fc24faa91c045dcf9b77933,
title = "Natural product derived immune-regulatory agents",
abstract = "We can now declare that the clinical goal of immune intervention as a therapeutic strategy for neoplastic, infectious, autoimmune and inflammatory diseases, has been achieved and in many instances obtained regulatory approval. Although, interest in and optimism for this approach has fluctuated, in the last 20 years, immunotherapy has progressed from trials with crude microbial mixtures and extracts to the sophisticated use of pure cultured bacterial, synthetized active moieties identified from crude extracts, analogues therefrom and agonists and antagonists identified during screening resulting in reproducible pharmacologically active compounds with multiple mechanisms of action. Our current understanding of the mechanism of action for immunoregulatory agents contributes to the future discovery of improved strategies to use these and future immunotherapies. In this review we have identified and discussed, those drugs that have been approved and or are in clinical development as immunoregulatory agents, emphasizing those derived from or associated with natural product.",
keywords = "Autoimmune, Infectious, Inflammatory diseases, Neoplastic",
author = "Talmadge, {James E}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.intimp.2016.02.025",
language = "English (US)",
volume = "37",
pages = "5--15",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",

}

TY - JOUR

T1 - Natural product derived immune-regulatory agents

AU - Talmadge, James E

PY - 2016/8/1

Y1 - 2016/8/1

N2 - We can now declare that the clinical goal of immune intervention as a therapeutic strategy for neoplastic, infectious, autoimmune and inflammatory diseases, has been achieved and in many instances obtained regulatory approval. Although, interest in and optimism for this approach has fluctuated, in the last 20 years, immunotherapy has progressed from trials with crude microbial mixtures and extracts to the sophisticated use of pure cultured bacterial, synthetized active moieties identified from crude extracts, analogues therefrom and agonists and antagonists identified during screening resulting in reproducible pharmacologically active compounds with multiple mechanisms of action. Our current understanding of the mechanism of action for immunoregulatory agents contributes to the future discovery of improved strategies to use these and future immunotherapies. In this review we have identified and discussed, those drugs that have been approved and or are in clinical development as immunoregulatory agents, emphasizing those derived from or associated with natural product.

AB - We can now declare that the clinical goal of immune intervention as a therapeutic strategy for neoplastic, infectious, autoimmune and inflammatory diseases, has been achieved and in many instances obtained regulatory approval. Although, interest in and optimism for this approach has fluctuated, in the last 20 years, immunotherapy has progressed from trials with crude microbial mixtures and extracts to the sophisticated use of pure cultured bacterial, synthetized active moieties identified from crude extracts, analogues therefrom and agonists and antagonists identified during screening resulting in reproducible pharmacologically active compounds with multiple mechanisms of action. Our current understanding of the mechanism of action for immunoregulatory agents contributes to the future discovery of improved strategies to use these and future immunotherapies. In this review we have identified and discussed, those drugs that have been approved and or are in clinical development as immunoregulatory agents, emphasizing those derived from or associated with natural product.

KW - Autoimmune

KW - Infectious

KW - Inflammatory diseases

KW - Neoplastic

UR - http://www.scopus.com/inward/record.url?scp=84960837003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960837003&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2016.02.025

DO - 10.1016/j.intimp.2016.02.025

M3 - Article

C2 - 26968760

AN - SCOPUS:84960837003

VL - 37

SP - 5

EP - 15

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

ER -